News

Ferring Bets Up to $1.38 Billion on Shorter IVF: What the Gameto Deal Means for Labs

Ferring and Gameto deal worth up to $1.38 billion: what it means for IVF labs

· IVF Automation News

Summary

On 27 October 2026, Ferring Pharmaceuticals and Gameto announced a signed agreement under which Ferring would acquire Gameto for up to $1.3825 billion, tied to development, regulatory and commercial milestones. Gameto's Fertilo, a stem-cell-based approach to maturing eggs outside the body, remains investigational in the US and is not FDA-approved.

One of the world's best-known fertility drugmakers has agreed to buy a company that hopes to reduce how much hormone stimulation IVF needs. If the deal closes, it will be one of the clearest signs yet that egg maturation in the lab, rather than in the body, is moving from the edge of reproductive medicine towards its commercial core.

The deal

According to the Gameto and Ferring joint announcement dated 27 October 2026, Ferring Pharmaceuticals and Gameto have signed an agreement under which Ferring would acquire Gameto. The deal is worth up to $1.3825 billion, subject to development, regulatory and commercial milestones. Completion is still subject to customary and other closing conditions, and the two companies will continue to operate independently until then. BioPharma Dive reported that Ferring did not disclose the upfront payment, and that Gameto has raised $127 million since it was founded in 2020.

Both companies are clear about one point. The announcement states that Gameto's in vitro maturation (IVM) programme is investigational in the United States and has not been approved by the US Food and Drug Administration.

The science in plain language

In conventional IVF, patients usually receive around two weeks of daily hormone injections so that several eggs mature inside the ovary before retrieval, as BioPharma Dive explains. In vitro maturation takes a different route: eggs are collected while still immature and finished in the laboratory.

Gameto's product, Fertilo, uses ovarian support cells derived from stem cells to help eggs mature outside the body, according to BioPharma Dive. The company claims this could reduce the need for hormone injections and shorten IVF and egg-freezing cycles to as little as three days. That is a company claim, not an established clinical result. BioPharma Dive reports that Fertilo is cleared for use in Australia and parts of Latin America, and that Phase 3 testing is under way in the US.

What it means for the lab

For embryologists, IVM moves part of the biology from the ovary to the incubator. Labs that adopt it would need validated protocols for handling immature oocytes, timing maturation checks and documenting each step. Training and competency records would matter as much as the medium itself.

For lab managers, any new culture system brings practical questions: incubator capacity, media lot tracking, quality-control logs and witnessing at each extra handling step. These are the same areas where digital tracking and audit trails already help labs.

For clinic owners and fertility specialists, the deal is a signal about direction, not a reason to change practice today. Fertilo's US approval depends on Phase 3 results and FDA review, and the payments are milestone-based. Independent, peer-reviewed outcome data will decide how widely clinicians use it.

India and global perspective

We found no announcement of Fertilo approval or availability in India. Any medical device or biological product here would go through Indian regulators, and clinics would have to meet the ART (Regulation) Act 2021 for records and registry reporting. For Indian labs, the near-term value is in watching the Phase 3 data and the regulatory path rather than in planning purchases.

Globally, the deal arrives during a busy week for IVF technology. On 26 October, UCSF and robotics company Conceivable Life Sciences announced plans for an AI and robotics IVF centre, according to Medtech Insight. Earlier in October, Overture Life announced the US launch of its ICSI.A robotic ICSI workstation, in a Business Wire press release. Taken together, investment is flowing both into lab automation and into ways of changing the treatment cycle itself.

Commercial opportunities

If IVM-based workflows grow, demand could rise for compatible incubators, consumables, lot-traceable media, training and lab software that records new protocol steps. Vendors serving Indian labs may want to follow the regulatory path closely. Large pharma ownership could also speed up global distribution, though neither company has given a timeline.

Outlook

The next milestones to watch are the deal's closing, the US Phase 3 results and any regulatory filings. Until peer-reviewed results are published, labs should treat shorter-cycle claims with caution, and watch closely.

Listing on IVF Automation? Vendors of IVF lab equipment and software can add a free directory listing.

Sources

  1. Gameto and Ferring joint announcement, Gameto / Ferring Pharmaceuticals, 27 Oct 2026 (company announcement, promotional)
  2. BioPharma Dive, “Ferring to acquire next-gen IVF startup Gameto for up to $1.4B”, Delilah Alvarado, 27 Oct 2026 (industry press)
  3. Medtech Insight, UCSF and Conceivable Life Sciences centre, announced 26 Oct 2026 (industry press)
  4. Overture Life, Business Wire, Oct 2026 (press release, promotional)

Tags: Ferring, Gameto, Fertilo, in vitro maturation, IVM, IVF industry, fertility M&A, embryology lab

Information only, not medical advice.

Get IVF Automation Weekly

The week's verified IVF industry news in your inbox.